Is Supernus Pharmaceuticals, Inc. overvalued?

Supernus Pharmaceuticals, Inc. (SUPN) looks undervalued — trading about 72% below its fair value.

Undervalued

Price

$44.40

Fair value

$76.55

Current P/E

12.9

Normal P/E

22.3

Market cap

$2.57B

Dividend yield

0.0%

Return on equity

-10.4%

Sector

Healthcare

Fair value compares SUPN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks